

Ryosuke Okamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1126274/publications.pdf>

Version: 2024-02-01

44
papers

1,910
citations

331259

21
h-index

288905

40
g-index

44
all docs

44
docs citations

44
times ranked

3482
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. <i>Nature Medicine</i> , 2019, 25, 744-750.	15.2	443
2	Analysis of <i>NTRK</i> Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for <i>NTRK</i> -Targeted Therapeutics. <i>JCO Precision Oncology</i> , 2018, 2018, 1-20.	1.5	201
3	Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. <i>Nature Communications</i> , 2020, 11, 4965.	5.8	172
4	<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. , 2020, 8, e000438.		117
5	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 6248-6256.	3.2	89
6	MHC-I genotype and tumor mutational burden predict response to immunotherapy. <i>Genome Medicine</i> , 2020, 12, 45.	3.6	70
7	Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis. <i>Clinical Cancer Research</i> , 2017, 23, 833-844.	3.2	65
8	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 130.	6.9	64
9	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2139-2145.	1.9	50
10	Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study. <i>Genome Medicine</i> , 2021, 13, 155.	3.6	44
11	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Onc Immunology</i> , 2020, 9, 1708065.	2.1	41
12	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. <i>International Journal of Cancer</i> , 2021, 148, 702-712.	2.3	41
13	Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	37
14	Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1303-1315.	1.0	33
15	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	30
16	Lower Incidence of Postoperative Pulmonary Complications Following Robot-Assisted Minimally Invasive Esophagectomy for Esophageal Cancer: Propensity Score-Matched Comparison to Conventional Minimally Invasive Esophagectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 639-647.	0.7	30
17	SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	29
18	Multicenter analysis of transanal tube placement for prevention of anastomotic leak after low anterior resection. <i>Journal of Surgical Oncology</i> , 2017, 116, 989-995.	0.8	29

#	ARTICLE	IF	CITATIONS
19	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. <i>Molecular Oncology</i> , 2021, 15, 67-79.	2.1	28
20	Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2021, 27, 2792-2797.	3.2	27
21	Impact of intraoperative blood loss on morbidity and survival after radical surgery for colorectal cancer patients aged 80 years or older. <i>International Journal of Colorectal Disease</i> , 2016, 31, 327-334.	1.0	23
22	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
23	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1852-1862.	1.9	22
24	The role of periodic serum CA19-9 test in surveillance after colorectal cancer surgery. <i>International Journal of Clinical Oncology</i> , 2017, 22, 96-101.	1.0	20
25	Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. <i>JCI Insight</i> , 2021, 6, .	2.3	20
26	Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pancreatic cancer setting. <i>International Journal of Cancer</i> , 2020, 146, 566-576.	2.3	19
27	High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. <i>International Journal of Cancer</i> , 2021, 148, 2839-2847.	2.3	19
28	Targeting fusions for improved outcomes in oncology treatment. <i>Cancer</i> , 2020, 126, 1315-1321.	2.0	14
29	Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. <i>International Journal of Cancer</i> , 2020, 146, 3450-3460.	2.3	14
30	Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. <i>Molecular Oncology</i> , 2020, 14, 1242-1251.	2.1	14
31	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA TP53 Mutations—A Perspective from a Real-World Precision Medicine Cohort. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2612-2620.	1.9	10
32	External validation of a genitourinary cancer-specific prognostic scoring system to predict survival for patients with bone metastasis (modified B-FOM scoring model): Comparison with other scoring models in terms of accuracy. <i>Journal of Bone Oncology</i> , 2021, 26, 100344.	1.0	10
33	Local control of sphincter-preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis. <i>Annals of Gastroenterological Surgery</i> , 2017, 1, 199-207.	1.2	8
34	Proposal of a stage-specific surveillance strategy for colorectal cancer patients: A retrospective analysis of Japanese large cohort. <i>European Journal of Surgical Oncology</i> , 2018, 44, 449-455.	0.5	8
35	Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. <i>Molecular Oncology</i> , 2022, 16, 2575-2584.	2.1	8
36	Long-Term Outcomes of Laparoscopic Radical Gastrectomy for Highly Advanced Gastric Cancer: Final Report of a Prospective Phase II Trial (KUGC04). <i>Annals of Surgical Oncology</i> , 2021, 28, 8962-8972.	0.7	7

#	ARTICLE	IF	CITATIONS
37	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. <i>JCO Precision Oncology</i> , 2022, 6, e2000508.	1.5	7
38	Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. <i>Oncologist</i> , 2020, 25, e1803-e1806.	1.9	6
39	Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. <i>JCO Precision Oncology</i> , 2021, 5, 1687-1698.	1.5	6
40	Precision oncology: the intention-to-treat analysis fallacy. <i>European Journal of Cancer</i> , 2020, 133, 25-28.	1.3	4
41	Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. <i>European Journal of Cancer</i> , 2021, 149, 184-192.	1.3	4
42	Identification of high-risk stage I colon and rectal cancer patients: a retrospective analysis of a large Japanese cohort. <i>International Journal of Colorectal Disease</i> , 2022, 37, 1403-1410.	1.0	3
43	Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. <i>Npj Precision Oncology</i> , 2022, 6, 18.	2.3	1
44	Variant allele fraction of genomic alterations in circulating tumor DNA (%ctDNA) correlates with SUV in PET scan. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 307-312.	1.0	0